Mira Pharma - MIRA STOCK NEWS

MIRA Pharmaceuticals announced positive preclinical results for Ketamir-2, an oral ketamine analog, suggesting it as a potential superior alternative to traditional ketamine for treating depression and treatment-resistant depression (TRD). The study conducted by Pharmaseed revealed that Ketamir-2 showed higher efficacy and safety compared to oral ketamine in male mice, with significant improvements in locomotor activity, reduced anxiety, and antidepressant effects. Unlike ketamine, Ketamir-2 can be administered orally, promising better patient compliance and is not a controlled substance under DEA rules. MIRA plans to submit an Investigational New Drug Application (IND) to the FDA later this year to initiate human trials.

Mira Pharmaceuticals announced that its novel drug MIRA-55 has been ruled by the DEA as not being a controlled substance. This decision eliminates regulatory barriers for manufacturing, research, and commercialization. MIRA-55, aimed at treating neuropathic pain, anxiety, and cognitive decline, shows promise in enhancing memory and cognitive performance without the adverse effects associated with THC in marijuana. The drug also demonstrates stable anti-anxiety effects and reduced intoxicating effects, providing a significant advantage over traditional cannabis. With access to large neurological and cannabis markets, MIRA-55 represents a promising value for the company.

MIRA Pharmaceuticals (NASDAQ: MIRA) is in advanced talks with Memorial Sloan Kettering Cancer Center (MSK) to evaluate MIRA's novel oral ketamine analog, Ketamir-2, for cancer-related pain and depression. This collaboration could validate Ketamir-2's potential and expand its application beyond depression and PTSD. MSK currently treats refractory cancer pain with intravenous ketamine, but Ketamir-2 may offer a more convenient oral alternative with higher bioavailability and a better safety profile. The study will compare Ketamir-2's efficacy to traditional ketamine in rodent models. MIRA also collaborates with Pharmaseed to explore Ketamir-2's effects on neuropathic pain. Successful preclinical results could accelerate FDA approval and create non-dilutive funding opportunities. Cancer pain affects 44% of patients, with 31% experiencing moderate to severe pain, and 25% suffering from depression.

Mira Pharmaceuticals has announced significant advancements in preclinical trials for Ketamir-2, an oral ketamine analog aimed at treating PTSD, depression, and neuropathic pain, including cancer pain. The company plans to submit an Investigational New Drug (IND) application to the FDA by year-end, aiming for human trials in 2025.

In collaboration with Pharmaseed, MIRA is testing Ketamir-2's efficacy in severe PTSD using rat models. Another study with Biotrial will evaluate the drug's locomotor effects in mice. MIRA has also initiated toxicological studies with Frontage Laboratories and improved the manufacturing process to reduce costs.

The potential market for Ketamir-2 is substantial, with PTSD affecting 8 million adults annually in the U.S. and the market for PTSD treatments projected to reach $26 billion by 2031.

MIRA Pharmaceuticals, Inc. shares updates on the pre-clinical studies of Ketamir-2, a potential treatment for major mental health disorders. Ketamir-2, a novel oral ketamine analog, shows promising results for treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. The compound demonstrates excellent stability in blood, safe metabolism, and optimal protein binding. The company aims to file an IND with the FDA by year-end for human testing.

Dr. Itzchak Angel, a renowned pharmaceutical executive with over 40 years of experience, joins MIRA Pharmaceuticals as the new Chief Scientific Advisor. His expertise in drug development and regulatory approval is expected to accelerate MIRA's research and development pipeline, focusing on novel treatments for neurologic and neuropsychiatric disorders.

MIRA Pharmaceuticals, Inc. announced a research collaboration with Pharmaseed to conduct pre-clinical studies on the use of Ketamir for patients with Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD). The studies aim to investigate the antidepressant properties of Ketamir and position it for an initial IND application in 2024. Ketamir is designed to address the challenges presented by MDD and PTSD, offering administration ease and aiming for fewer side effects.

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) has released new data from artificial intelligence (AI) simulations that show significant potential advantages of MIRA1a over plant-based medical marijuana in treating anxiety, appetite, and cognition. The simulations, conducted in collaboration with InSilicoTrials, indicate MIRA1a's potential as a superior anti-anxiety treatment with increased cognition and without the appetite increase associated with THC. MIRA1a's predicted ability to initiate a response at three pivotal brain receptors, as well as its unique properties and potential as an intervention for neurological disorders, position it as a promising development in neuropharmacological therapies.

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced new data showing Ketamir-2's potential to reshape the landscape of depression treatment. The oral bioavailability of Ketamir-2 is predicted to be around 80%, with projections of annual sales reaching $3 billion by 2035, and estimates rising to up to $7.8 billion.